Expansion of Strategic Patent Applications and Registrations for Research Results
First written in FY2019. 8 of 10 entries say "Advanced", first in FY2020-Q2. Latest entry: FY2024.
4 other companies' latest entry also says "Other".
- FY2024Decline in the number of patent applications and registrationsAnnual report
「As a result, as of 31 July 2024, the Group had filed or registered 125 patents, comprising 36 domestic registrations, 23 overseas registrations, and 66 pending applications. Going forward, it plans to increase new applications and the registration of patents already filed in order to further secure its intellectual property rights.」
The number of patent applications and registrations fell from the 211 disclosed for the previous fiscal year to 125, while the policy of increasing new applications and registrations remains in place. - FY2024-Q3AdvancedAnnual report
「We are also actively pursuing AI-based drug discovery through a specialist team. As a result, in February 2024 we obtained Patent No. 7437558 for technology that enables antibodies to be produced more efficiently by modifying antigens through computer-aided design.」
The Company obtained a patent in February 2024 for an AI drug discovery technology that modifies antigens through computer-aided design. - FY2023AdvancedAnnual report
「As a result, as of 31 July 2023, the Group had filed or registered 211 patents, comprising 119 domestic registrations, 28 overseas registrations, and 64 pending applications. Going forward, it plans to increase new applications and the registration of patents already filed in order to further secure its intellectual property rights.」
The number of patent applications and registrations increased from 143 in the previous fiscal year to 211. For the anti-PAD4 antibody, the Company received a notice of allowance in Europe following the United States. - FY2023-Q1AdvancedAnnual report
「In August 2022, the Company received a notice of allowance from the United States Patent and Trademark Office for the anti-PAD4 antibody patent (application number US15/555,808).」
There was concrete progress in securing rights to the Company’s research成果 through the allowance of the anti-PAD4 antibody patent in the United States. - FY2022AdvancedAnnual report
「As a result, as of 31 July 2022, the Group had filed or registered 143 patents, comprising 96 domestic registrations, 19 overseas registrations, and 28 pending applications. Going forward, it plans to increase new applications and the registration of patents already filed in order to further secure its intellectual property rights.」
The number of patent applications and registrations increased from 57 to 143, with the breakdown of domestic and overseas registrations and pending applications also specified. - FY2021AdvancedAnnual report
「As a result, as of 31 July 2021, the Group had filed or registered 57 patents, comprising 25 domestic registrations, 10 overseas registrations, and 22 pending applications. Going forward, it plans to increase new applications and the registration of patents already filed in order to further secure its intellectual property rights.」
The number of patent applications and registrations increased from 42 at the end of July 2019 to 57. - FY2021-Q3AdvancedAnnual report
「The Company succeeded in identifying the optimal blend ratio for improving the scalp flora from among several dozen ingredients intended for scalp care, and filed a patent application for the ingredient in February 2021.」
The Company filed a patent application in February 2021 for a newly developed ingredient intended for scalp flora and is advancing efforts to secure rights to its research成果. - FY2020-Q3AdvancedAnnual report
「The patent relating to the anti-FSTL1 antibody filed in 2016, titled “Anticancer and metastasis-suppressing agents using FSTL1 and combination agents thereof,” was granted in the United States following its grant in Japan, accelerating development.」
With respect to securing rights to its research成果, the patent relating to the FSTL1 antibody has been granted in the United States following its grant in Japan. - FY2020-Q2AdvancedAnnual report
「The patent relating to the anti-FSTL1 antibody filed in 2016, titled “Anticancer and metastasis-suppressing agents using FSTL1 and combination agents thereof,” was granted in Japan, accelerating development.」
The patent relating to the FSTL1 antibody was granted in Japan, marking concrete progress in securing rights to the Company’s research成果. - FY2019First statedAnnual report
「As of 31 July 2019, the Company had filed or registered 42 patents, comprising 10 pending applications, 25 domestic registrations, and 7 overseas registrations. Going forward, it plans to increase new applications and the registration of patents already filed in order to further secure its intellectual property rights.」
The Company reported 42 patent applications and registrations and stated its policy of increasing both new applications and registrations going forward.